{"result": "(\"entity\"<|>AMERICAN THYROID ASSOCIATION<|>ORGANIZATION<|>The American Thyroid Association (ATA) is a professional organization that provides guidelines and recommendations regarding thyroid health and treatment, including prophylactic thyroidectomy for genetic mutation carriers.)\n##\n(\"entity\"<|>MEN2A<|>EVENT<|>MEN2A is a genetic condition that increases the risk of developing certain types of tumors, particularly medullary thyroid carcinoma (CMT) and pheochromocytoma.)\n##\n(\"entity\"<|>MEN2B<|>EVENT<|>MEN2B is a genetic condition characterized by the development of medullary thyroid carcinoma and other endocrine tumors, often with a more aggressive clinical course.)\n##\n(\"entity\"<|>RET<|>PERSON<|>RET is a proto-oncogene whose mutations are associated with multiple endocrine neoplasia syndromes, influencing the risk and management of thyroid cancer.)\n##\n(\"entity\"<|>CMT<|>EVENT<|>CMT, or medullary thyroid carcinoma, is a type of thyroid cancer that can occur in individuals with mutations in the RET gene, particularly in MEN2A and MEN2B.)\n##\n(\"entity\"<|>FEO<|>EVENT<|>FEO, or pheochromocytoma, is a tumor of the adrenal gland that can occur in patients with MEN2A and MEN2B syndromes.)\n##\n(\"entity\"<|>HYPERPARATHYROIDISM<|>EVENT<|>Hyperparathyroidism (HPP) is a condition that can occur in patients with MEN2A, characterized by excessive secretion of parathyroid hormone.)\n##\n(\"entity\"<|>CALCITONIN<|>PERSON<|>Calcitonin is a hormone produced by the thyroid gland that is used as a marker in the diagnosis and management of medullary thyroid carcinoma.)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>MEN2A<|>The American Thyroid Association provides recommendations for the management and treatment of patients with MEN2A, including guidelines for prophylactic thyroidectomy.<|>8)\n##\n(\"relationship\"<|>AMERICAN THYROID ASSOCIATION<|>MEN2B<|>The American Thyroid Association provides recommendations for the management and treatment of patients with MEN2B, including guidelines for prophylactic thyroidectomy.<|>8)\n##\n(\"relationship\"<|>RET<|>MEN2A<|>Mutations in the RET gene are responsible for the development of MEN2A, influencing the risk of medullary thyroid carcinoma and other tumors.<|>9)\n##\n(\"relationship\"<|>RET<|>MEN2B<|>Mutations in the RET gene are responsible for the development of MEN2B, influencing the risk of medullary thyroid carcinoma and other tumors.<|>9)\n##\n(\"relationship\"<|>CMT<|>MEN2A<|>CMT is a common manifestation in patients with MEN2A, often necessitating surgical intervention based on genetic risk factors.<|>7)\n##\n(\"relationship\"<|>CMT<|>MEN2B<|>CMT is a common manifestation in patients with MEN2B, often necessitating surgical intervention based on genetic risk factors.<|>7)\n##\n(\"relationship\"<|>FEO<|>MEN2A<|>FEO is a potential complication in patients with MEN2A, requiring monitoring and management as part of the syndrome.<|>6)\n##\n(\"relationship\"<|>FEO<|>MEN2B<|>FEO is a potential complication in patients with MEN2B, requiring monitoring and management as part of the syndrome.<|>6)\n##\n(\"relationship\"<|>HYPERPARATHYROIDISM<|>MEN2A<|>Hyperparathyroidism is a condition that can occur in patients with MEN2A, necessitating monitoring and potential treatment.<|>6)\n##\n(\"relationship\"<|>CALCITONIN<|>CMT<|>Calcitonin levels are used as a biomarker for the diagnosis and management of medullary thyroid carcinoma.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 3%), que origina un CMT menos agresivo que la mutación M918T. Raramente se han descrito pacientes MEN2B con las mutaciones en tándem: V804M + E805K, V804M + Y806C y V804M + S904C, que se caracterizan por un inicio más tardío del CMT y agresividad variable.\n\nLa misma mutación puede ocasionar diferentes manifestaciones clínicas y distinta penetrancia y agresividad del CMT en la misma familia o en diferentes familias; esto sugiere que otros cambios genéticos u otros modificadores genéticos son responsables de estas diferencias fenotípicas.\n\nEsta correlación genotipo-fenotipo se ha utilizado para realizar recomendaciones respecto a la edad para realizar una tiroidectomía total profiláctica y comenzar el cribado bioquímico para feocromocitoma e hiperparatiroidismo.\n\nEn los portadores genéticos de mutación RET asintomáticos existe consenso sobre la necesidad de realizar una tiroidectomía total profiláctica, pero no sobre la edad en que se debe realizar; para algunos autores debería hacerse antes del desarrollo del CMT, y para otros, antes de la extensión del CMT fuera de la glándula, lo que garantizaría en ambas situaciones su curación a largo plazo.\n---\n# METABOLISMO FOSFOCÁLCICO, TUMORES NEUROENDOCRINOS Y MEN\n\nEn 2015, la American Thyroid Association (ATA) Task Force actualizó sus recomendaciones sobre la edad en la que se debería realizar una tiroidectomía total profiláctica. Estas recomendaciones están basadas en un modelo que utiliza la correlación genotipo-fenotipo para estratificar las mutaciones RET en tres niveles de riesgo diferentes: moderado (MOD), alto riesgo (H) y categoría de más alto riesgo (HST) (tabla 4).\n\n## Tabla 4. Niveles de riesgo de las mutaciones del protooncogén RET y recomendaciones de cribado y tratamiento (ATA, 2015)\n\n| NIVEL DE RIESGO | MUTACIONES | EDAD PARA TIROIDECTOMÍA TOTAL PROFILÁCTICA | EDAD DE INICIO PARA EL CRIBADO DE FEO Y HPP (ANUAL) |\n|-----------------|------------|--------------------------------------------|----------------------------------------------------|\n| Muy alto (HST) | M918T | <6 meses | 11 años (no HPP) |\n| Alto (H) | C634, A883F V804M + E805K, V804M + Y806C, V804M + S904C | 5 años o antes si calcitonina elevada | 11 años (no en mutaciones asociadas a MEN2B) |\n| Moderado (MOD) | Resto de mutaciones | Controles anuales de calcitonina y ecografía Tiroidectomía total si calcitonina elevada | 16 años |\n\nFEO: feocromocitoma; HPP: hiperparatiroidismo primario.\n\nEsta nueva clasificación tiene en cuenta la gran heterogeneidad en la presentación clínica en pacientes con la misma mutación, la mayor sensibilidad y especificidad de los ensayos de inmunoquimioluminiscencia para la determinación de calcitonina, y recientes estudios que han demostrado que el nivel de calcitonina plasmática puede diferenciar entre hiperplasia de las células C, CMT confinado en la glándula tiroidea y CMT con expansión ganglionar. Por ello, para orientar el momento y el tipo de intervención quirúrgica recomiendan valorar el genotipo, la ecografía tiroidea y el valor de la calcitonina basal (la mayoría de los autores consideran que dada su sensibilidad no es necesario realizar test de estímulo).\n\nLa tiroidectomía total estaría recomendada para la mayoría de los pacientes portadores genéticos de MEN2A si tienen una calcitonina basal normal o inferior a 40 pg/ml, nódulo tiroideo de menos de 5 mm y sin metástasis ganglionares detectadas por ecografía. En MEN2B está recomendada en niños menores de 6 meses sin evidencia de enfermedad, o nódulo tiroideo de menos de 5 mm, y sin metástasis en los ganglios linfáticos.\n\nLa tiroidectomía total y la disección del compartimento central del cuello (niveles VI y VII) está recomendada en pacientes con MEN2A con calcitonina basal superior a 40 pg/ml o evidencia de metástasis en los ganglios linfáticos.\n\nReferencias:\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n- Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Madrid: Sociedad Española de Endocrinología y Nutrición. 2015. Capítulo 3. Neoplasia Endocrina Múltiple. Disponible en: https://manual.seen.es\n- Wells S, Asa SL, Dralle H, Elisei R,\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}